ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1335

Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Abstract Number: 1343

Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and -2)
Abstract Number: 1808

Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial
Abstract Number: 0068

Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Randomization Studies
Abstract Number: 0061

Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin
Abstract Number: 1600

Has the COVID 19 Pandemic Impacted the Management of Chronic Musculoskeletal Pain?
Abstract Number: 1923

Has the Incidence of Total Joint Arthroplasty in Rheumatoid Arthritis Decreased in the Era of Biologics Use? A Population-based Incident Cohort Study 1995–2015
Abstract Number: 0880

Health Information Use by SLE Patients Pre and During COVID-19
Abstract Number: 1605

Health Related Quality of Life in Rheumatology Outpatients with COVID-19 from New York City over the Course of the Pandemic
Abstract Number: 1271

Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Abstract Number: 1039

Healthcare Resource Utilization and Costs of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review
Abstract Number: 0144

Healthcare Utilization and Costs Following Kawasaki Disease in Ontario, Canada
Abstract Number: 1852

Healthcare Utilization and Economic Burden in Systemic Sclerosis
Abstract Number: 0894

Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus
Abstract Number: 0670

Hemochromatosis Is Associated with CPPD Through Iron’s Effect on Bone

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].